A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence
Status:
Unknown status
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to gather systematic clinical data on whether aripiprazole, a
partial dopamine agonist, beneficially affects schizophrenia plus cocaine dependence
subjects. Since aripiprazole has established effects against schizophrenia, the study focuses
on whether aripiprazole concurrently reduces co-morbid cocaine dependence in schizophrenia
plus cocaine dependence sufferers compared to a standard typical antipsychotic treatment
(perphenazine). The working hypothesis states that subjects in the aripiprazole treatment arm
of the study will give fewer cocaine positive urine specimens as compared to the perphenazine
control arm.